Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder

Jadwiga Najib
1–3

1Division of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, 2Department of Pharmacy, 3Department of Psychiatry, St Luke’s-Roosevelt Hospital Center, New York, NY, USA

Abstract: Attention-deficit/hyperactivity disorder is one of the most common neurobehavioral disorders defined by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity. Symptoms begin in childhood and may persist into adolescence and adulthood. Currently available pharmacological treatment options for attention-deficit/hyperactivity disorder in children and adolescents include stimulants that are efficacious and well tolerated; however, many of these preparations require multiple daily dosing and have the potential for abuse. Lisdexamfetamine dimesylate, the first prodrug stimulant, was developed to provide a longer duration of effect. It demonstrates a predictable delivery of the active drug, d-amphetamine, with low interpatient variability, and has a reduced potential for abuse. A literature search of the MEDLINE database and clinical trials register from 1995–2011, as well as relevant abstracts presented at annual professional meetings, on lisdexamfetamine dimesylate in children and adolescents were included for review. This article presents the pharmacokinetic profile, efficacy, and safety of lisdexamfetamine dimesylate for the treatment of attention-deficit/hyperactivity disorder in children and, more recently, in adolescents.

Keywords: lisdexamfetamine dimesylate, prodrug stimulant, attention-deficit and hyperactivity disorders, safety, efficacy, children, adolescents

Introduction

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders that pediatricians and child psychiatrists see in practice, and which can profoundly affect the well-being, academic achievement, and social interactions of children.1 In late 2011, the American Academy of Pediatrics updated their ADHD diagnosis and evaluation guidelines and expanded the age group, previously 6–12 year olds, to include younger preschool children (ages 4 years and 5 years) and adolescents (<18 years of age).2 In the United States, approximately 9% of children in a representative sample of 8–15 year olds met the criteria for ADHD;3 likewise, the occurrence rate in adolescents between 13–18 years of age was approximately 8% according to the National Comorbidity Survey Adolescent Supplement Replication epidemiologic survey.4

The underlying pathophysiology of ADHD has not been clearly identified, although neurobiological, genetic, and environmental factors have been implicated. Since the catecholaminergic neurotransmitter system is associated with executive and cognitive functions, disturbances in the regulation of norepinephrine and dopamine have been implicated in ADHD pathogenesis.5 Treatment guidelines published by the American Academy of Child and Adolescent Psychiatry and the American Academy
of Pediatrics, as well as by international consensus, note the strong evidence for safety and efficacy of stimulant medications in the treatment of childhood and adolescent ADHD.2,4–8 Other treatment options for ADHD include alpha-2 adrenergic agonists (eg, clonidine, guanfacine), heterocyclic antidepressants (eg, tricyclic antidepressants, bupropion, venlafaxine), arousal agents/hypothalamic center activators (eg, modafinil), and atomoxetine—a nonstimulant selective norepinephrine reuptake inhibitor.

**ADHD management issues in adolescents and children**

ADHD first appears in childhood and manifests as a persistent pattern of inattention, hyperactivity, and impulsivity that is more frequent and severe than typically observed in children at a comparable level of age or development.9 The disorder may affect the child’s life, leading to low self-esteem; higher injury rates due to accidents; poor performance at school, sports, or after-school activities; and conflict with family, friends, and teachers.1,10 Untreated ADHD is associated with risk for school failure or dropout, alcohol and/or substance abuse, teen pregnancies, delinquency, and other behavior and discipline problems.10,11 Symptoms of ADHD often persist into adolescence and adulthood and result in pervasive impairments across multiple life domains, including home, school, peers, and extracurricular activities.1,12

Stimulants, which include amphetamine derivatives (dextroamphetamine sulfate, mixed amphetamine salts), and nonamphetamines, (methylphenidate and dexamethylphenidate) are available in a variety of immediate and extended release formulations. The immediate release preparations, due to their shorter duration, require more frequent administration, usually two to three times a day.9,13 This may result in a need for medication supply and reliance on the school nurse for administration, and has the potential for nonadherence and social stigmatism.14 The long-acting oral stimulant preparations are usually dosed once a day and their duration of activity is generally 7–12 hours, depending on the product.15,16 They offer improved adherence and greater dosing convenience; however, concerns about the abuse potential of stimulants exist and have led to the development of newer formulations addressing this issue.

Lisdexamfetamine dimesylate (LDX), the first prodrug stimulant, was developed to provide a longer duration of effect and reduce the potential for abuse. Although ADHD is apparent across the lifespan, the focus of this paper is limited to reviewing LDX—a prodrug of d-amphetamine that has been approved since 2007—for the treatment of ADHD in children and, more recently, in adolescents (since 2010). Published reports of clinical trials with LDX in children and adolescents with ADHD (ie, <18 years of age) were identified in a systematic literature search of MEDLINE (PubMed and EMBASE) from 1995–2011. A search for registered clinical trials using LDX for ADHD within clinicaltrials.gov was also conducted and reviewed. Abstracts presented at the annual meetings of the American Psychiatric Association, the American Academy of Child and Adolescent Psychiatry, and the Canadian Academy of Child and Adolescent Psychiatry were reviewed and included if judged to be relevant.

**Pharmacology and pharmacokinetics of LDX**

LDX distinguishes itself from other central nervous system stimulants and long-acting preparations due to its prodrug properties and pharmacokinetic profile.17 LDX contains d-amphetamine covalently bonded to L-lysine, and undergoes enzymatic hydrolysis to convert the pharmacologically inactive molecule to the active drug moiety, d-amphetamine, primarily in the blood by red blood cells.18 It appears that the high capacity absorption and enzymatic conversion may be responsible for the consistent and reproducible pharmacokinetic profile of LDX. Since the enzymatic process appears to be high-capacity, saturation is unlikely to happen at therapeutic doses; however, at dosages greater than 130–150 mg, the levels are attenuated due to saturation of the enzymatic hydrolysis, suggesting reduced potential for toxicity in an overdose.19

Following oral administration of LDX, the pharmacokinetic profile of d-amphetamine was reportedly similar in pediatric (aged 6–12 years) and adolescent (aged 13–17 years) ADHD patients compared with healthy adults.20 In a study of 18 pediatric patients (aged 6–12 years) following ingestion of LDX as a single oral 30, 50, or 70 mg dose, the time to maximum concentration of the prodrug molecule LDX was 1 hour, while the time to maximum concentration of d-amphetamine was 3.5 hours. Peak d-amphetamine levels were dose-proportional and exhibited low interpatient variability. After oral administration of LDX, the serum elimination half-life of d-amphetamine ranged from 8.6–10.4 hours, consistent with data reported from earlier studies.21

Since food does not affect absorption of LDX, the drug may be administered with breakfast or the contents of the capsule may be dissolved in water prior to oral administration.
In contrast, food has been shown to prolong the time to maximum concentration of d-amphetamine from extended release mixed amphetamine salts (MAS XR) by 2.5 hours compared with the fasted state. Once-daily administration of LDX (30, 50, or 70 mg/day) compared with MAS XR at equivalent total d-amphetamine base content (10, 20, or 30 mg/day, respectively) in children (aged 6–12 years) noted that the time to maximum concentration of LDX was 3.5 times less variable than with the MAS XR. LDX showed low patient-to-patient pharmacokinetic variability, and the release of d-amphetamine was more predictable in patients who took 70 mg LDX than in patients who took 30 mg MAS XR (the equivalent total d-amphetamine base content), suggesting consistent drug delivery among patients. When administered orally, the onset of clinical effect was noted within 2 hours, comparable to the clinical effect observed with MAS XR. LDX maintained efficacy throughout the 12-hour testing period and more recently was shown to be effective 1.5–13 hours postingestion.

Following biotransformation, LDX is hepatically metabolized and nearly the entire dose is renally eliminated as either amphetamine related compounds or inactive metabolites. LDX has a low potential for drug–drug interactions as it is not metabolized by cytochrome P450 enzymes and thus does not inhibit the majority of these enzymes. However, any interactions with LDX would likely be caused by d-amphetamine and its metabolites.

The biotransformation and not the dissolution of intact LDX appears to be responsible for the rate of delivery of the active metabolite. Since LDX is a prodrug subject to enzymatic hydrolysis following ingestion, and not a controlled release delivery vehicle, it is not likely to be affected by changes in normal gastrointestinal transit times or variations in gastric acidity. Variations in gastric pH have not been shown to affect the absorption of LDX, suggesting that no drug interactions should occur with LDX and medications that lower the gastrointestinal pH. However, interpatient variability in gastric pH and gastrointestinal motility may affect the metabolism of some long-acting preparations of methylphenidate, and impact the delivery of the delayed release active moiety. Likewise, acidifying and alkalinizing agents may reduce or increase blood levels of amphetamine from MAS XR preparations, respectively. The low interpatient variability observed with LDX may not alleviate the need to titrate doses, but may aid in the process of developing a dosing regimen for patients, and reduce the likelihood of achieving either subtherapeutic or supratherapeutic levels.

Efficacy data
Pediatric
Efficacy of LDX has been established in several clinical trials in children (aged 6–12 years) who met the Diagnostic and Statistical Manual of Mental Disorders (fourth edition, text revision) criteria for a diagnosis of the combined or predominantly hyperactive-impulsive subtype of ADHD (Table 1).

The first study by Biederman et al, a Phase II trial, compared LDX with MAS XR and placebo in a laboratory classroom environment and used three standard efficacy scales during observations made over a 12-hour period. These included the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP)-Deportment scale – which uses an independent observer to assess classroom symptoms of ADHD, the Permanent Product Measure of Performance – a validated test consisting of age-appropriate math questions, and the Clinical Global Impression (CGI) scale – a validated tool for assessing global improvements in symptoms over time. This three-treatment, three-period, crossover study noted that both LDX 30, 50, or 70 mg and MAS XR 10, 20, or 30 mg significantly improved measures of efficacy compared to placebo on all three scales. Improvements over placebo were observed within 2 hours of the LDX dose, with the greatest effect occurring at approximately 6 hours, and treatment effects were seen at 12 hours postdose, the last assessment time point. A clinically meaningful difference between the two active groups was not demonstrated. A post hoc analysis suggested that treatment with LDX, administered at doses containing equivalent amounts of d-amphetamine as MAS XR, resulted in greater improvement in ADHD symptoms as evidenced by the CGI-Improvement assessment.

Biederman et al also evaluated the efficacy of LDX 30, 50, and 70 mg in a double-blind, randomized, placebo-controlled, Phase III study involving 290 children with ADHD. A significant treatment difference favoring LDX compared to placebo was observed on the ADHD Rating Scale Version IV (ADHD-RS-IV), Conners’ Parent Rating Scale-Revised Short Version, and CGI-Improvement with all doses of LDX. The most improvement in the mean ADHD-RS-IV scores and in Connor’s Parent Rating Scale-Revised Short Version was observed in patients who received LDX 70 mg. Additionally, the CGI-Improvement scores significantly improved from baseline to treatment endpoint for all LDX doses compared with placebo.

Lopez et al, in a post hoc analysis, noted improvements at all three assessment times on the Connor’s Parent Rating Scale.
<table>
<thead>
<tr>
<th>Author</th>
<th>Study population: number of patients (n), patient age</th>
<th>Duration, study design</th>
<th>Primary efficacy measurements</th>
<th>Results</th>
<th>AEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biederman et al</td>
<td><em>n</em> = 52, 6–12 years</td>
<td>6 weeks, MC, R, DB, PC, and active-controlled three-treatment, three-period, crossover study in a controlled classroom environment. Three cohorts: each cohort received LDX 30, 50, or 70 mg; MAS XR 10, 20, or 30 mg and placebo.</td>
<td>LS mean of the average scores of SKAMP-D at endpoint.</td>
<td>Significant improvement noted for LDX (30, 50, and 70 mg combined doses) and MAS XR (10, 20, and 30 mg combined doses) in mean (SD) SKAMP-D score (both treatments 0.8 [0.1]) versus placebo (1.7 [0.1]) (both treatments P &lt; 0.0001 versus placebo).</td>
<td>During the DB part of the study, AEs reported for LDX, MAS XR, and placebo, respectively, were: insomnia (8%, 2%, 2%), decreased appetite (6%, 4%, 0%), anorexia (4%, 0%, 0%), upper respiratory tract infection (2%, 2%, 0%), vomiting (0%, 2%, 4%), and upper abdominal pain (0%, 2%, 4%). Abdominal pain, headache, and labile affect were all reported as zero for all three treatment groups.</td>
</tr>
<tr>
<td>Wigal et al</td>
<td><em>n</em> = 117, 6–12 years</td>
<td>6 weeks, 4-week MC, laboratory school study, open-label, dose optimization LDX 30, 50, or 70 mg, followed by R, DB, PC, two-way crossover phase (1 week each × 2).</td>
<td>LS mean difference of SKAMP-D.</td>
<td>Significant improvement on SKAMP-D with LDX from 1.5 hours to 13 hours postdose compared to placebo (P &lt; 0.005). Mean difference in LS means for SKAMP-D by optimized LDX dose groups: 30 mg, −0.70 (−0.88, −0.52); 50 mg, −0.68 (−0.84, −0.52); 70 mg, −0.96 (−1.30, −0.63).</td>
<td>TEAEs during dose optimization and crossover phase, respectively, were: decreased appetite (47%, 6%), insomnia (27%, 4%), headache (17%, 5%), irritability (16%, 1%), upper abdominal pain (16%, 2%), and labile affect (10%, 0%).</td>
</tr>
<tr>
<td>Lopez et al</td>
<td><em>n</em> = 52, 6–12 years</td>
<td>Post hoc analysis of Biederman et al's trial.</td>
<td>CGI-I score of one at endpoint.</td>
<td>Significantly higher number of patients on LDX (32%) versus MAS XR (16%) (P = 0.0386) with “very much improved” CGI-I score (placebo was 2%).</td>
<td>NA</td>
</tr>
<tr>
<td>Biederman et al</td>
<td><em>n</em> = 290, 6–12 years</td>
<td>4 weeks, MC, R, DB, PC, FD titration, parallel groups: LDX 30, 50, or 70 mg versus placebo.</td>
<td>Mean change from baseline to endpoint in ADHD-RS-IV total score.</td>
<td>Significant improvement in ADHD-RS-IV noted with all doses of LDX versus placebo (−21.8, −23.4, −26.7, −6.2, respectively; all P &lt; 0.001). Significant improvement noted in weekly ADHD-RS-IV total score change from baseline starting at week one (P &lt; 0.001), with all three doses of LDX.</td>
<td>AEs for LDX 30 mg, 50 mg, 70 mg, and placebo, respectively, were: decreased appetite (37%, 31%, 49%), insomnia (16%, 16%, 23%), upper abdominal pain (14%, 7%, 15%), headache (10%, 10%, 16%, 10%), irritability (11%, 8%, 10%, 0%), vomiting (7%, 5%, 14%, 4%), weight loss (6%, 3%, 19%, 1%), nausea (4%, 3%, 11%, 3%), dizziness (7%, 5%, 3%, 0%), nasopharyngitis (6%, 4%, 6%, 6%), nasal congestion (4%, 0%, 0%, 0%), cough (3%, 1%, 0%, 6%), and dry mouth (3%, 3%, 8%, 0%).</td>
</tr>
<tr>
<td>Lopez et al</td>
<td><em>n</em> = 290, 6–12 years</td>
<td>Post hoc analysis of Biederman et al's trial.</td>
<td>Improvements on the CPRS-R:S and its subscales (ADHD index, hyperactivity, oppositional, and cognition) analyzed at 10 am, 2 pm, and 6 pm.</td>
<td>Improvement from baseline for all doses of LDX at all times versus placebo: CPRS-R:S (P &lt; 0.0001); CPRS-R:S ADHD Index (P &lt; 0.0001); CPRS-R:S Hyperactivity (P &lt; 0.0001); CPRS-R:S Cognition (P &lt; 0.0001); and CPRS-R:S Oppositional at 10 am and 2 pm only (P &lt; 0.01).</td>
<td>NA</td>
</tr>
</tbody>
</table>
**Jain et al**  
*n = 290, 6–12 years*

Post hoc analysis of Biederman et al’s trial to evaluate clinical efficacy of LDX in children with/without prior MPH treatment. Dual criteria of $\geq 30\%$ reduction in ADHD-RS-IV total score from baseline and a CGI-I score of one or two at endpoint. Of 290 randomized patients, 28 received MPH treatment at screening, of which 26 remained symptomatic (nonremitters). Of nonremitters on prior MPH therapy, clinical response observed in 15 on LDX and three on placebo. NNT (95% CI) for one patient to achieve symptomatic remission and a clinical response, respectively, with LDX at treatment endpoint was 2.0 (1.21–6.63) (for both) in nonremitters on prior MPH versus 2.1 (1.74–2.72) and 1.8 (1.51–2.22) in the overall study population.

Mean (SE) change from baseline at endpoint for LDX versus placebo: pulse 0.3 (1.20) to 4.1 (1.17) bpm versus −0.7 (1.17) bpm; SBP 0.4 (1.08) to 2.6 (1.05) mmHg versus 1.3 (1.05) mmHg; DBP 0.6 (0.93) to 2.3 (0.91) mmHg.

**Wigal et al**  
*n = 117, 6–12 years*

Post hoc analysis of Wigal et al’s trial. Effect size for SKAMP-D, interaction between sex or age and treatment. LS mean postdose effect size of LDX on SKAMP-D: $-1.73 (0.18)$. LS mean SKAMP scores for females improved more than for males in all measures at all time points. LS mean SKAMP scores for ages 10–12 years were lower (less impairment) versus ages 6–9 years.

**Findling et al**  
*n = 272, 6–12 years*

12 months, MC, open-label extension; LDX dose optimized to 30, 50, or 70 mg for the first 4 weeks, then maintained for 11 months. Mean change from baseline to endpoint in ADHD-RS-IV total score. At endpoint, LDX (all doses) showed a $60\%$ improvement by decreasing ADHD-RS-IV total mean scores $-27.2 (1.30)$ compared with baseline ($P < 0.0001$); improvement in decreasing ADHD-RS inattentive and hyperactivity-impulsivity subscale scores: $-1.34 (7.0)$ and $-13.8 (7.0)$, respectively, compared with baseline (both $P < 0.001$). Improvements in ADHD-RS-IV were consistent from week four onwards. With all doses of LDX, AEs were: decreased appetite (33%), weight loss (18%), headache (18%), insomnia (17%), upper abdominal pain (11%), upper respiratory tract infection (11%), irritability (10%), nasopharyngitis (10%), vomiting (9%), cough (7%), and influenza (6%). The majority of AEs occurred within the first 2 months; after 4 months, only decreased appetite and weight loss occurred in $5\%$ of patients. TEAs in dose optimization phase in males and females, respectively, were: decreased appetite (48%, 45%), insomnia (31%, 16%), headache (18%, 13%), irritability (16%, 16%), upper abdominal pain (16%, 13%), labile affect (11%, 7%), and nausea (7%, 13%). TEAs in crossover phase in males and females, respectively, were: decreased appetite (6%, 7%), insomnia (6%, 0%), headache (5%, 7%), irritability (1%, 0%), upper abdominal pain (2%, 0%), labile affect (0%, 0%), and nausea (1%, 4%).

**Findling et al**  
*n = 318, 6–12 years*

7 weeks, MC, open-label, dose optimization and maintenance; LDX: 20, 30, 40, 50, 60, or 70 mg. Mean change from baseline to endpoint in ADHD-RS-IV total score. At endpoint, LDX (all doses) showed a $69\%$ improvement by decreasing ADHD-RS-IV total mean scores $-28.6 (10.9)$ compared with baseline ($P < 0.0001$). There were significant improvements in the inattention (−15.2) and hyperactivity/impulsivity subscales (−13.4) at endpoint ($P < 0.0001$).

Mean (SE) change from baseline at endpoint for LDX versus placebo: pulse 0.3 (1.20) to 4.1 (1.17) bpm versus −0.7 (1.17) bpm; SBP 0.4 (1.08) to 2.6 (1.05) mmHg versus 1.3 (1.05) mmHg; DBP 0.6 (0.93) to 2.3 (0.91) mmHg.

**TEAs in dose optimization phase in males and females, respectively, were: decreased appetite (48%, 45%), insomnia (31%, 16%), headache (18%, 13%), irritability (16%, 16%), upper abdominal pain (16%, 13%), labile affect (11%, 7%), and nausea (7%, 13%). TEAs in crossover phase in males and females, respectively, were: decreased appetite (6%, 7%), insomnia (6%, 0%), headache (5%, 7%), irritability (1%, 0%), upper abdominal pain (2%, 0%), labile affect (0%, 0%), and nausea (1%, 4%).**
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Author</th>
<th>Study population: number of patients (n), patient age</th>
<th>Duration, study design</th>
<th>Primary efficacy measurements</th>
<th>Results</th>
<th>AEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turgay et al</td>
<td>n = 318, 6–12 years</td>
<td>Post hoc analysis of Findling et al's trial.</td>
<td>BRIEF scores.</td>
<td>Mean (SD) change from baseline to endpoint with LDX all doses: GEC –17.9 (12.5); BRI –15.4 (12.6); and MCI –17.6 (12.3) (all P &lt; 0.0001).</td>
<td>As noted in Findling et al.36</td>
</tr>
<tr>
<td>Wigal et al</td>
<td>n = 26, 6–12 years</td>
<td>4–5 weeks, LDX dose optimization 30, 50, or 70 mg and open-label, laboratory school study (1 week).</td>
<td>Reading performance assessed via GORT-4.</td>
<td>Nonsignificant trend toward improvement in both reading and reading accuracy (P &lt; 0.088 and P &lt; 0.0679, respectively).</td>
<td>NA</td>
</tr>
<tr>
<td>Findling et al</td>
<td>n = 314, 13–17 years</td>
<td>4 weeks, MC, R, DB, PC, FD, parallel-groups with LDX 30, 50, or 70 mg versus placebo.</td>
<td>Mean change from baseline to endpoint in ADHD-RS-IV total score.</td>
<td>Mean change from baseline in ADHD-RS-IV total score was –18.3 (1.25), –21.1 (1.28), –20.7 (1.25) for LDX 30, 50, or 70 mg versus placebo –12.8 (1.25) (P &lt; 0.0056 versus placebo for each).</td>
<td>TEAE (≥5%) for LDX 30, 50, or 70 mg and placebo were: decreased appetite (37%, 27%, 37%, 3%), headache (12%, 17%, 15%, 13%), insomnia (9%, 10%, 14%, 4%), decreased weight (4%, 9%, 15%, 0%), irritability (8%, 3%, 10%, 4%), nasopharyngitis (3%, 5%, 1%, 1%), and upper respiratory tract infection (3%, 5%, 5%, 8%). Mean (SE) change from baseline at endpoint for vital signs with LDX 30, 50, or 70 mg and placebo: SBP –0.8 (1.22), 0.3 (1.01), 1.7 (1.21), and 2.2 (1.04) mmHg; DBP –0.5 (1.05), 0.4 (0.84), 3.4 (0.80), and 0.5 (0.97) mmHg, pulse 5.0 (1.18), 3.8 (1.37), 5.4 (1.27), and 0.8 (1.36) bpm. TEAEs (≥5%) were: upper respiratory tract infections (21.9%), decrease in appetite (21.1%), headache (20.8%), weight loss (16.2%), irritability (12.5%), insomnia (15.5%), nasopharyngitis (7.2%), influenza (6.8%), dizziness (5.3%), and dry mouth (5.3%). As noted in Childress et al.42</td>
</tr>
<tr>
<td>Childress et al</td>
<td>n = 269, 13–17 years</td>
<td>52 weeks, 4-week study from Findling et al, then 48-week open-label extension.</td>
<td>Changes in YQOL-R from baseline to endpoint.</td>
<td>Mean YQOL-R transformed total perceptual score improved from 79.8 (11.28) at baseline to 83.9 (11.0) at endpoint (P &lt; 0.0001).</td>
<td>As noted in Childress et al.42</td>
</tr>
<tr>
<td>Childress et al</td>
<td>n = 269, 13–17 years</td>
<td>Post hoc analysis of Childress trial.</td>
<td>Mean change from baseline to endpoint in ADHD-RS-IV total score.</td>
<td>Significant difference between both active treatment groups and placebo from baseline in ADHD-RS-IV total scores (LDX -18.6, OROS-MPH -13, both P &lt; 0.001).</td>
<td>TEAEs (≥10%) were: decreased appetite, headache, insomnia, decreased weight, nausea, and anorexia.</td>
</tr>
<tr>
<td>Coghill et al</td>
<td>n = 336, 6–17 years</td>
<td>7 weeks, MC, R, DB, PC, parallel groups: LDX 30, 50, or 70 mg or OROS-MPH 18, 36, or 54 mg versus placebo.</td>
<td>Mean change from baseline to endpoint in ADHD-RS-IV total score.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Post hoc analysis of Findling et al's trial.

EESC total scores.

At endpoint, significant mean change from baseline in EESC total score -7.4 (18.3) (P < 0.0001); and for each subscale: -2.1 (9.6) for positive emotions (P < 0.0002), -2.5 (7.7) for emotional flatness (P < 0.0001); and -2.8 (5.2) for emotional lability (P < 0.0001).

Post hoc analysis of Wigal et al's trial.

Safety profile of LDX on cardiovascular measurements.

Changes in physiological measures for stimulant-naive patients versus prior stimulant exposed patients: pulse 1.62 versus -4.57 bpm; SBP 5.38 versus -4.14 mmHg; DBP 1.00 versus 0.57 mmHg; PR interval 0.46 versus 1.00 msec; QRS duration 1.54 versus 0.57 msec; QT interval 1.38 versus 10.00 msec; heart rate-corrected QT interval 5.15 versus -0.57 msec.

Frequency of most significant (P < 0.05) AEs for stimulant-naive and prior stimulant exposed patients, respectively, were: trouble sleeping (77%, 21%), stomach pain (62%, 21%), dizziness (0%, 29%), and hyperfocus (31%, 0%).

Post hoc analysis of Giblin and Strobel's trial.

Change from baseline to endpoint in LPS via PSG.

PSG data: mean change from baseline to endpoint not significant from placebo and LDX-treated patients for LPS, WASO, and TST. Significant only for NAW in LDX-treated patients compared to placebo (P < 0.0001). Mean improvement with LDX in ADHD-RS-Iv of 28.7 from baseline (P < 0.0001).

All TEAEs were mild or moderate. The most common for LDX versus placebo were: headache (five versus one), increased pulse (five versus zero), and increased blood pressure (two versus one).
Scale-Revised Short Version total score and subscales of ADHD Index, Hyperactivity, and Cognition, regardless of the patient’s baseline disease severity. They found that children with significant clinical ADHD symptoms – despite prior treatment with methylphenidate – improved with LDX treatment, and efficacy outcomes were similar to the results of the overall study population, regardless of the LDX dose utilized.

Another post hoc analysis by Jain et al evaluated the clinical efficacy of LDX in children with and without prior methylphenidate treatment at screening. They found that children with ADHD had improved behavioral symptoms with LDX treatment, regardless of whether they had prior methylphenidate treatment.

In Biederman et al’s Phase III study, the effect size of LDX treatment was reported at 30, 50, and 70 mg to be 1.21, 1.34, and 1.60, respectively. A meta-analysis of stimulants used for ADHD in children and adolescents before concluding the superiority of LDX over other stimulants.

In a simulated classroom setting involving 117 children with ADHD, Wigal et al conducted a 4-week open-label, dose optimization study of LDX (30, 50, 70 mg/day) followed by a 2-week randomized, placebo-controlled, two-way crossover phase. Changes from baseline SKAMP-Depormnt, SKAMP-Attention, and Permanent Product Measure of Performance scores up to 13 hours postdose were significantly higher in children treated with LDX compared to placebo. ADHD-RS-IV total scores and subscale scores improved from baseline for all LDX doses during the 4-week open-label phase, and during the 2 weeks of the crossover period.

All patients had a CGI-Improvement rating of “very much improved” or “much improved” at the end of the 4 weeks, and 82.3% of patients had such scores for the crossover period. These continued improvements throughout the day reinforce the benefits derived from the extended duration of action observed with LDX treatment from the previous studies. Post hoc analysis of the above study assessed interaction between sex or age and treatment, and assessed effect sizes for SKAMP. Although both females and males demonstrated improvement on all assessments at postdose time points, females and children between the ages of 10–12 years were noted to have less impairment in SKAMP ratings.

A long-term trial by Findling et al assessed the safety and efficacy of LDX treatment over a 12-month period in 272 children. LDX was titrated from 30 mg to 70 mg over a period of 4 weeks, and patients continued open-label LDX treatment for an additional 11 months. Clinician-rated ADHD-RS-IV scores improved by a mean of 27.2 points, and improvements occurred during each of the first 4 weeks and were maintained during the study period. More than 80% of patients were rated as improved at trial endpoint, and more than 95% of patients had a CGI-Improvement score rated as “very much improved” or “much improved” after completing 12 months of treatment.

Another prospective open-label LDX dose optimization trial was conducted by Findling et al in 318 children. In this 7-week study evaluating LDX 20, 30, 40, 50, 60, or 70 mg, a 69% average relative improvement from baseline to endpoint in the ADHD-RS-IV total score was observed. Approximately 89% of patients at endpoint were classified as CGI-Improvement “very much improved” or “much improved,” and on the parent-rated Parental Global Assessment scale, 85% were rated as improved. Additionally, 76% of parents reported they were “very satisfied” with DX treatment and 87% stated they would “absolutely” or “probably” continue using LDX as treatment. In a post hoc analysis, efficacy was assessed with the Behavior Rating Inventory of Executive Function – a validated instrument that measures components of executive functioning in children 5–18 years of age. Two indices were used: the Behavioral Regulation Index (inhibit, shift, and emotional control) and Metacognition Index (initiate, working memory, plan/organize, organization of materials, and monitor); these two indices together comprise a Global Executive Composite score. Significant improvements in the Behavior Rating Inventory of Executive Function indices for all dosages of LDX were demonstrated without regards to ADHD subtype, comorbid psychiatric symptoms, sex, or baseline executive function impairment category.

Wigal et al assessed effects of LDX on reading performance in 26 children with ADHD in a modified laboratory school study with an open-label, dose-optimization phase of a daily dose of 30, 50, or 70 mg LDX. Following 4–5 weeks of optimal dose titration, the Gray Oral Reading Test-4 – a measure of rate, accuracy, and comprehension – was administered at baseline and at 3–4 hours postdose. At study endpoint, LDX significantly reduced symptoms of ADHD from baseline, as evidenced by ADHD-RS-IV subtypes of hyperactivity/impulsivity and inattention (both P < 0.0001). No differences were noted for reading accuracy or comprehension. However, reading rate improved, especially among children with higher verbal fluid reasoning without additional symptomatology of neurodevelopmental delay.
Adolescents

In late 2010, the FDA approved LDX for use in adolescents based on results from a double-blind, placebo-controlled, 4-week, forced-dose, Phase III trial. This study by Findling et al was conducted in 45 United States sites in 309 adolescents (aged 13–17 years) who met Diagnostic and Statistical Manual of Mental Disorders (fourth edition, text revision) criteria for ADHD with at least moderately symptomatic ADHD (ADHD-RS-IV score of ≥28, baseline mean 37–38.5). All patients randomized to LDX were initiated on 30 mg for the first week of treatment and patients assigned to the 50 mg and 70 mg dose were escalated by 20 mg weekly until they reached their assigned dose. This forced-dose titration of 3 weeks was followed by a 1-week dose maintenance phase. The primary and secondary efficacy measures included the ADHD-RS-IV, CGI-Improvement, and Youth Quality Of Life-Research Version (YQOL-R) scores from baseline to endpoint. At endpoint, changes in ADHD-RS-IV total scores were significantly greater for each LDX dose compared to placebo (all P < 0.0056). CGI-Improvement scores showed that 69.1% of participants treated with LDX (all doses combined) were rated “very much improved” or “much improved” at endpoint compared to 39.5% of participants on placebo (P < 0.0001). There was no statistically significant improvement in the YQOL-R scores at endpoint for LDX compared to placebo.

Patients who participated in the above study were eligible to enroll in a 48-week maintenance phase, open-label extension of the original 4-week study to further assess the long-term safety and efficacy of LDX. Patients were seen once monthly and optimized doses were either continued or titrated upwards or downwards to a maximum of 70 mg/day. The mean (standard deviation) ADHD-RS-IV total score at baseline was 38 (7), and the mean change from baseline to endpoint was −26.2 (9.75) (P < 0.001). At all follow-up visits, significant changes in subscale scores of inattention and hyperactivity/impulsivity were observed: change score of −15.1 (6.05) with a baseline of 22.6 (3.35) and change score of −11.1 (5.89) with a baseline of 15.4 (6.9), respectively (P < 0.001). Improvements in CGI-Improvement scores of “very much improved” or “much improved” were noted in 91.2% of patients at week 4 (dose optimization phase) and in 87.2% at maintenance phase endpoint. Childress et al also evaluated the quality of life in this long-term open-label trial of LDX: the YQOL-R transformed total perceptual score was 79.8 (11.3) at baseline, 84.6 (9.4) at week 28, and 83.9 (11.0) at endpoint (all P < 0.001). Likewise, the YQOL-R domain scores for self, relationship, and environment all improved significantly from baseline to week 28 (all P < 0.001) and to endpoint (all P < 0.001); the general domain improved from baseline to endpoint (P < 0.027). Patients with poor participant-perceived scores at baseline showed improvement at endpoint on YQOL-R domain scores (ranging 9.8–17.6) compared to those without poor baseline scores (ranging 0.4–5.1). Likewise, the change in score from baseline for the YQOL-R transformed total perceptual score was 12.5 and 2.9, respectively, in the same patient subgroups.

A recent Phase III study conducted at 48 sites in Europe enrolled 336 patients (aged 6–17 years) with at least moderate symptoms, defined as a baseline ADHD-RS-IV total score of ≥28 (mean 49). Patients were randomized to LDX, osmotic release oral system methylphenidate (OROS-MPH), or placebo over a period of 7 weeks. Doses of LDX and OROS-MPH were optimized to 30, 50, or 70 mg/day and 18, 36, or 54 mg/day, respectively. The primary comparison was LDX compared to placebo with no formal comparisons intended between LDX and ORSO-MPH. From baseline to endpoint, significant differences between both active treatment groups and placebo in ADHD-RS-IV total scores were observed (P < 0.001). At study endpoint, improvements in CGI-Improvement scores were noted in 78% of patients in the LDX group, 61% in the OROS-MPH group, and 14% in the placebo group. The effect size for LDX was reported at 1.80 compared with 1.26 for OROS-MPH.

Safety data

Since LDX is a prodrug ultimately converted to d-amphetamine, the expected adverse effect profile of LDX is similar to that of other amphetamine products. LDX was well tolerated in all the clinical trials described above with similar incidence of adverse effects noted in the short-term trials and the long-term open-label trials. Most treatment-emergent adverse events were of mild-to-moderate intensity for all doses of LDX, with no reports of death. The majority of adverse events were noted to occur during the dose titration and dose optimization phases, and most adverse events declined over time (Table 1).

In the Phase II analog classroom study in children aged 6–12 years, the adverse events were consistent with those observed in other stimulants, including MAS XR. In this study, decreased appetite was noted in both treatment groups (LDX 6%, MAS XR 4%), and anorexia occurred only in the LDX group (4%). A small but significant increase in diastolic blood pressure and pulse were noted among patients treated with LDX (4.6 mmHg and 6.7 bpm) and MAS XR (2.7 mmHg and 5.3 bpm) compared to placebo 2.5 hours.
following stimulant administration. Other assessments, including systolic blood pressure, heart rate-corrected QT intervals, and electrocardiogram (ECG) parameters, did not differ between treatment and placebo groups.22

The incidence of adverse events with LDX reported in the three Phase III trials and one open-label short-term study in children aged 6–12 years that were significantly greater than that reported in the placebo group included: appetite suppression (33%–47%), insomnia (17%–27%), headache (12%–18%), upper abdominal pain (11%–15%), irritability (10%–16%), and weight loss (9%–18%).21,29,35,36 No clinically significant changes were observed in laboratory values or physical exams. Small mean increases in blood pressure and pulse and small reductions in weight were observed in the pediatric studies, and were consistent with the known effects of stimulant use.

The occurrence of insomnia and vomiting from the open-label, long-term study in children was noted to be dosedependent. At doses of 30, 50, or 70 mg, the occurrence of insomnia and vomiting were 4% and 3%, 9% and 4%, and 17% and 6%, respectively. No patient had a QT, Fridericia’s heart rate-corrected QT, or Bazett’s heart rate-corrected QT interval of ≥500 milliseconds at any treatment visit, and no changes in ECG measurements were determined to be clinically meaningful. Mean (standard deviation) changes from baseline in vitals were 0.7 (10) mmHg for systolic blood pressure, 0.6 (8.3) mmHg for diastolic blood pressure, and 1.4 (13.7) bpm for pulse. In the second 8-week treatment period of the study, decrease only in weight and appetite occurred in ≥5% of patients, indicating that tolerability to LDX improved over time.35

In the dose optimization phase of the 13-hour laboratory school study, the most commonly observed adverse events in males were upper abdominal pain, headache, labile affect, and insomnia; in females it was nausea and decreased weight. During the crossover phase for those receiving LDX, males experienced more upper abdominal pain and insomnia, and females reported more nausea and headache.34

A post hoc analysis of the 7-week, open-label, dose optimization study with LDX aimed to describe the reliability and clinical relevance of change in emotional expression using the Expression and Emotion Scale for Children (EESC), a parent-rated report that evaluates both positive and negative aspects of emotional expression.43 At endpoint, improvement was noted from baseline in EESC total score. Additionally, a significant decrease from baseline for each EESC subscale (emotional flatness, positive emotions, and emotional lability) score was noted in patients at their last study visit, suggesting there was no mean worsening of emotional expression scores. Findings from this study are limited due to a lack of a placebo group for comparison and normative data for the EESC; however, results may suggest that LDX does not adversely affect emotional expression overall for many participants and, for some, improvement from baseline was achieved.

The most frequently reported adverse events in the 4-week, forced-dose titration study involving adolescents aged 13–17 years taking LDX were decreased appetite, headache, insomnia, weight loss, and irritability.39 Small mean increases in pulse and blood pressure from baseline to endpoint were observed in LDX-treated patients compared to placebo. At endpoint, a pulse of ≥100 bpm was noted in 5%, 1%, and 3% of patients treated with LDX 30, 50, or 70 mg, respectively, compared to 1% on placebo. Systolic blood pressure of ≥120 mmHg was observed in 30%, 28%, and 27% of patients treated with LDX 30, 50, and 70 mg, respectively, compared to 25% on placebo at endpoint. Mean increase in Fridericia’s heart rate-corrected interval at endpoint was observed for all three LDX doses (0.2–2.7 milliseconds) compared to placebo (2.8 milliseconds), with no differences across treatment groups. Two participants had postbaseline ECG findings determined to be clinically significant (Fridericia’s heart rate-corrected QT interval of 479 milliseconds and 413 milliseconds, respectively), which led to study discontinuation. This differed from the earlier aforementioned pediatric studies where no clinically significant cardiac conduction changes were observed. No new or unexpected safety concerns were observed in laboratory or physical examinations, and overall the treatment-emergent adverse events were consistent with previous LDX studies and previously described effects of amphetamines in children and adults.

The safety analysis from the long-term, open-label extension study in adolescents noted that most treatment-emergent adverse events were mild to moderate in severity and 15 serious adverse events were reported in ten subjects; only syncope (three episodes) was thought to be treatment related. At endpoint, small mean (standard deviation) increases in systolic blood pressure (2.3 [10.53] mmHg), diastolic blood pressure (2.5 [8.37]) mmHg, and pulse (6.3 [12.74]) bpm were observed from baseline. No clinically significant ECG changes at endpoint or clinically meaningful trends in laboratory were observed.40

In the adolescent European study, treatment-emergent adverse events were reported in 65%, 72%, and 57% of patients in the OROS-MPH, LDX, and placebo groups, respectively.42
assessments on height, weight, and body mass index up to had tachycardia and one had blood pressure in the experienced adverse events outside the normal range: one stimulant therapy. In the stimulant-naïve group, two patients children than in children who had prior exposure to cardiovascular effects were measured in stimulant-naïve and anorexia. Further analysis of the results from this first European, Phase III study of once-daily LDX are expected to be published soon.

The effect of LDX on growth of children has been evaluated by Faraone et al in an exploratory uncontrolled study from previous trials with LDX 30, 50, or 70 mg in 281 children (aged 6–13 years), with longitudinal assessments on height, weight, and body mass index up to 15 months. At baseline, children with ADHD were taller and heavier than average when compared to norms from the Centers for Disease Control and Prevention, and although children treated with LDX continued to grow in height, the growth delays were largest for weight and body mass index. Body mass index scores decreased significantly from baseline to endpoint ($t_{276} = 10.15; P < 0.0001$). Mean loss was also observed in expected weight (3.7 kg) and height (0.9 cm). This study did not separate out the effects of dose and duration; however, study findings did suggest that participants who received prior stimulant therapy had already experienced the bulk of their growth deficit prior to being treated with LDX. The delays were greatest for the heaviest and tallest children, those with the highest cumulative dose exposure, and those who had not received a prior stimulant therapy. The data from this study were similar to the results of the Multimodal Treatment Study of ADHD; both studies noted that stimulants are associated with growth delays and that these delays decreased over time.

To address the safety profile of LDX based on cardiovascular measurements, Wigal et al conducted a post hoc analysis of the investigation on reading performance in response to LDX in 27 children, of which 14 had prior stimulant exposure and 13 were stimulant naïve. More cardiovascular effects were measured in stimulant-naïve children than in children who had prior exposure to stimulant therapy. In the stimulant-naïve group, two patients experienced adverse events outside the normal range: one had tachycardia and one had blood pressure in the ≥95th percentile of normal age range.

A large retrospective cohort study assessed serious cardiovascular events from ADHD medications in over 1,2 million children and young adults aged 2–24 years (mean age at baseline 11 years), with over 2.5 million person-years of follow-up and over 370,000 person-years of current use of ADHD medications. Compared with nonusers, the adjusted rate of serious cardiovascular events did not differ significantly among individuals currently using ADHD medications nor among former users. Increased risk was associated with older age, concurrent use of an antipsychotic, a major psychiatric illness, serious cardiovascular condition, and a chronic illness. Although results from this study showed that use of ADHD medications did not increase the risk of serious cardiovascular events, the labeling for LDX – as with other amphetamine products – includes a boxed warning describing sudden cardiac death and serious cardiovascular adverse events with misuse of the medication. In 2008, the American Academy of Pediatrics issued a recommendation that children with ADHD be screened for cardiac problems prior to initiating therapy with stimulants. The recommendations include a physical exam and an evaluation for presence of an abnormal heart murmur, cardiovascular abnormalities, and Marfan syndrome. Since some cardiac conditions may not be detectable on routine physical exams, an ECG may be used. Later that year, a joint statement by the American Academy of Pediatrics and the American Heart Association stated that ECGs are not mandatory and that they may be performed at the discretion of the physician.

Giblin and Strobel assessed the mean change from baseline to week 7 on objective sleep measures via polysomnography in placebo- and LDX-treated participants. There were no statistically significant differences noted in both groups regarding latency to persistent sleep, wake time after sleep onset, or total sleep time. Only the number of awakenings after sleep onset significantly decreased in the LDX-treated group relative to baseline ($P < 0.0001$), possibly indicative of a more consolidated sleep. Parents/guardians in this study had extensive sleep hygiene counseling at each visit and appropriate sleep schedules were set for each study participant, which may have also contributed to the lack of sleep disturbances observed with LDX in this study. In comparison, earlier studies have reported an incidence of insomnia of 27% in children treated with LDX. The sample in Giblin and Strobel's study was small ($n = 24$) and the multifarious nature of findings warrant that these conclusions be interpreted cautiously as more studies need to be undertaken in larger samples in children with ADHD. Additionally, the majority of children in this study had received earlier stimulant therapy for ADHD, which may have made them less prone to experience insomnia. Wigal et al had also noted that in stimulant-naïve participants, 77% experienced “trouble sleeping” while 21% with prior stimulant exposure reported this effect.
Postmarketing data from a poison control review of LDX that involved five poison centers covering eight states noted the most common adverse events reported by the examining health care provider included tachycardia (73%), agitation (53%), dystonia (47%), insomnia (20%), hallucinations (20%), chest pain (13%), fasciculation (20%), and vomiting (13%). Additionally, abdominal pain, tremor, confusion, and seizures were each reported at 7%.51

A case of generalized alopecia has been described in a 5-year-old female following 5 days of treatment with LDX 30 mg.52 Two days following discontinuation of LDX, the alopecia was less marked. Eosinophilic hepatitis necessitating hospitalization in a 14-year-old male, whose only prescribed medication had been LDX 30 mg for the previous 5 months, resolved completely within 2 months following LDX discontinuation.53 In both the above reports, the Naranjo Scale yielded a score of seven, indicating probable medication-related event with LDX.

Goodman et al assessed the safety profile of LDX across age groups from three studies in children, adolescents, and adults.54 Common adverse events observed with LDX (all doses) versus placebo are listed in Table 2. The adverse events were similar across age groups, and results were consistent with the safety profile of long-acting stimulants. In children, the incidence of upper abdominal pain and decreased appetite was higher than in adults, while dry mouth and headache were higher in adults than in children.

Table 2 Summary of the safety profile of lisdexamfetamine dimesylate from three randomized, 4-week, double-blind, placebo-controlled, forced-dose titration studies in children, adolescents, and adults

<table>
<thead>
<tr>
<th>Measure</th>
<th>Children (6–12 years)</th>
<th>Adolescents (13–17 years)</th>
<th>Adults (18–55 years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common AE (&gt;10%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDX versus placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper abdominal pain</td>
<td>11.9% versus 5.6%</td>
<td>0.9% versus 3.9%</td>
<td>2.5% versus 1.6%</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>39% versus 4.2%</td>
<td>33.9% versus 2.6%</td>
<td>26.5% versus 1.6%</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>4.6% versus 0%</td>
<td>4.3% versus 1.3%</td>
<td>25.7% versus 3.2%</td>
</tr>
<tr>
<td>Headache</td>
<td>11.9% versus 9.7%</td>
<td>14.6% versus 13%</td>
<td>20.7% versus 12.9%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>18.8% versus 2.8%</td>
<td>11.2% versus 3.9%</td>
<td>19.3% versus 4.8%</td>
</tr>
<tr>
<td>Changes in vitals: least squares mean (SE) change from baseline to endpoint for LDX 30 mg, 50 mg, 70 mg, and placebo, respectively</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP, mmHg</td>
<td>0.4 (1.08), 1.8 (1.06)</td>
<td>–0.8 (1.22), 0.3 (1.01)</td>
<td>0.8 (0.77), 0.3 (0.77),</td>
</tr>
<tr>
<td></td>
<td>2.6 (1.05), 1.3 (1.05)</td>
<td>1.7 (1.21), 2.2 (1.04)</td>
<td>1.3 (0.75), –0.6 (1.05)</td>
</tr>
<tr>
<td></td>
<td>0.6 (0.93), 1.9 (0.92)</td>
<td>–0.5 (1.05), 0.4 (0.84)</td>
<td>0.8 (0.61), 1.1 (0.60),</td>
</tr>
<tr>
<td></td>
<td>2.3 (0.91), 0.6 (0.91)</td>
<td>3.4 (0.80), 0.3 (0.97)</td>
<td>1.6 (0.60), 1.1 (0.83),</td>
</tr>
<tr>
<td></td>
<td>0.3 (1.20), 2.0 (1.18)</td>
<td>5.0 (1.18), 3.8 (1.37)</td>
<td>2.8 (0.83), 4.2 (0.83),</td>
</tr>
<tr>
<td></td>
<td>4.1 (1.17), –0.7 (1.17)</td>
<td>5.4 (1.27), 0.8 (1.36)</td>
<td>5.2 (0.82), –0.0 (1.14)</td>
</tr>
<tr>
<td>Mean (SD) changes in body weight (lb) with LDX</td>
<td>–2.5 (3.37)</td>
<td>–4.8 (3.48)</td>
<td>–4.3 (4.49)</td>
</tr>
</tbody>
</table>


Abbreviations: AE, adverse event; DBP, diastolic blood pressure; LDX, lisdexamfetamine dimesylate; SBP, systolic blood pressure; SD, standard deviation; SE, standard error.
since they must be swallowed whole, and not be crushed, in order to preserve their long-acting effects. Studies note that the appetite suppression observed with LDX and other amphetamines may be more pronounced than that observed with methylphenidate products with similar duration of action.55 LDX demonstrated significant ADHD symptom improvement 1.5–13 hours following oral administration, from morning through homework and family time.23

The long duration of effect may be beneficial for adolescents, since their activities may extend beyond the regular school hours and into after-school activities, employment, and other responsibilities. On the other hand, the extended duration of action of this prodrug may be too long for some younger children. Although insomnia may be a concern for some patients due to LDX’s long duration of effect, in clinical trials it did not often result in discontinuation of the stimulant.

In addition to the long duration of action noted with LDX, a post hoc analysis by Jain et al31 of the Phase III trial by Biederman et al29 noted that children with significant clinical ADHD symptoms – despite prior treatment with methylphenidate – improved on LDX, regardless of dose, and had similar improvements in their symptoms as the overall study population. In the same Phase III trial, analysis of ADHD-RS-IV scores at treatment endpoint noted the effect size of LDX 30, 50, and 70 mg to be 1.21, 1.34, and 1.60, respectively.29 Faraone and Buitelaar, in a meta-analysis of stimulant medications used in children with ADHD, noted that regarding the number needed to treat (95% confidence interval) results, clinicians would need to treat two (1.7–2.2) patients with amphetamine compared with 2.6 (2.4–2.8) with methylphenidate for each positive outcome for total ADHD symptoms.32 The meta-analysis also noted that the largest effect size was similar to that observed in Biederman et al’s Phase III trial29 and the apparent superiority of LDX may be that it reflects greater efficacy of amphetamine compared to nonamphetamine (eg, methylphenidate) products, a finding noted by the meta-analysis and supported by a comparative review by Arnold.56 The difference in effect size between amphetamine and nonamphetamine stimulants (eg, methylphenidate) may be due to differences in the molecular mechanisms implicated in facilitating the dopaminergic neurotransmission, and although the pediatric trial by Biederman et al29 suggests that LDX is more efficacious than other psychostimulants, more clinical trials need to be undertaken to see if such findings can be replicated.

Clinicians need to be vigilant when prescribing stimulants as they may be abused or diverted, especially the immediate release formulations that have a quick onset of action. LDX requires oral ingestion to convert it from an inactive form to the active drug, d-amphetamine, thus making it less likely to be susceptible to misuse or abuse by other delivery routes (eg, inhalation, injection), and may also have benefit in a household where abuse or misuse is a concern. Support for the reduced abuse potential with oral and intravenous LDX relative to immediate release d-amphetamine has been described in adult non-ADHD subjects with a history of drug abuse.57,58 In those studies, the abuse-related liking scores for oral LDX at a dose of 150 mg (amphetamine base content equivalent to d-amphetamine 60 mg) were comparable to oral d-amphetamine 40 mg (an amphetamine-based dose equivalent to LDX 100 mg).57 Intravenous d-amphetamine 20 mg, but not intravenous LDX 50 mg, produced significantly more liking effects compared to placebo.58

Poor medication adherence rates among patients with ADHD occur across all ages, and may be more problematic among teenagers. Medication compliance may be affected by patient beliefs about the disorder; side effects of the medication; and, in adolescents, concerns about peer group acceptance and the stigma of the illness, or concerns about taking the medications. One review of prescription claims in children (<18 years) noted mean adherence rates (medication possession ratio ≥80%) during the school year and during the entire year, respectively, for immediate release stimulants (52.8% versus 37.2%), extended release stimulants (63.7% versus 52.1%), LDX (63.5% versus 47.6%), and nonstimulants (62.9% versus 52.5%). Additionally, mean adherence rates were higher during the school year than the entire year for long-acting agents (63.4% versus 53.3%) than for the short-acting agents (52.2% versus 37.2%).59 Symptoms of ADHD have an additional impact on the adaptive functioning and quality of life. Patrick et al found that adolescents with ADHD had a reported mean YQOL-R transformed total perceptual score of 75.2 compared to 82.2 for controls.60 The study by Childress et al noted that the scores at endpoint (83.9) were similar to that of controls, demonstrating the improved quality of life observed with LDX in that patient population.41

Antonacci et al assessed parents’ perceptions regarding the impact of ADHD and use of LDX in children via surveys (n > 11,000) in a real-world setting.61 Parents reported significant improvements in symptoms that caused substantial interference with school activities, homework, and family and social interactions (P < 0.01). Satisfaction with LDX was significantly higher than with their child’s previous treatment (P < 0.01). On average, tolerability, global improvement, convenience, and satisfaction with LDX were all highly rated and when asked about intention to continue treatment, 83% responded yes, 14% maybe, and 3% no.
LDX is commercially available in 20, 30, 40, 50, 60, and 70 mg capsules. Doses in children and adolescents should be initiated at 30 mg once daily in the morning, regardless of prior stimulant use. The dose may be increased by 10 mg or 20 mg/day at approximately weekly intervals to a maximum daily dose of 70 mg. Patients who have had prior exposure to stimulant therapy may tolerate titration of LDX to higher doses better than stimulant-naïve patients.45

Conclusion
The chronic nature of ADHD extends well beyond childhood and, in adolescents, may lead to a variety of risk-taking behaviors, which can have a significant adverse consequence for development and adult well-being. LDX, a prodrug of d-amphetamine, is a once-daily medication indicated for the treatment of ADHD in children and adolescents. Efficacy results in adolescents were consistent with the earlier findings in children, and the safety profile for LDX is similar to other currently marketed stimulants, with increases in blood pressure and pulse appearing to be dose-related. LDX has reduced toxicity in an overdose, and reduced liability for misuse and abuse. The extended duration of action observed with LDX provides sufficient time to control ADHD symptoms that extend beyond the school day and well into after-school activities, homework, and family time. Until new medications are discovered with a similar efficacy as the currently available stimulants, but with a better tolerated safety profile and reduced risk for abuse, stimulants—like LDX—will remain drugs of choice in managing ADHD.

Disclosure
The author reports no conflicts of interest in this work.

References


